Thermo Fisher Scientific launches Olink Target 48 Neuro-degeneration panel
Thermo Fisher Scientific has launched the Olink Target 48 Neurodegeneration panel, a targeted proteomics immunoassay designed to support neurodegenerative disease research. The panel provides simultaneous measurement of 41 key and emerging proteins with absolute quantification, optimised for plasma analysis using as little as 1µL of sample.
Addressing clinical research requirements
The new panel targets the increasing need for scalable, reproducible protein measurement tools in neurodegeneration research. With conditions such as Alzheimer’s disease, multiple sclerosis and Parkinson’s disease on the rise, clinical pipelines require translational biomarkers for drug development and disease monitoring.
The panel measures biomarkers selected for relevance across Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease and other neurodegenerative disorders. The system utilises Olink’s established Proximity Extension Assay (PEA) technology to deliver absolute quantification whilst enabling high-throughput studies with precious biobank samples.
Clinical validation and applications
Charlotte Teunissen, professor in neurochemistry at the Department of Laboratory Medicine at Amsterdam University Medical Center, served as an early access user. She noted: “The Target 48 Neurodegeneration panel is a critical tool that enables the detection and quantification of key and emerging neurodegenerative disease biomarkers from plasma and cerebrospinal fluid samples. By generating quantitative data, it ensures reproducible results across and within longitudinal studies, moving a step forward towards clinical utilisation.”
Yan Zhang, President of the Proteomic Sciences business at Thermo Fisher Scientific, commented: “Neurological diseases are complex, multifactorial and urgently in need of translational insights especially with non-invasive proteomic biomarkers for longitudinal monitoring. The panel, designed in close collaboration with leading clinical researchers, offers absolute quantification of multiplex key biomarkers to monitor disease progression and therapeutic responses to power precision medicine.”
System integration and availability
The Target 48 Neurodegeneration panel joins the existing Olink portfolio, including Target 48 Cytokine and Target 48 Immune Surveillance panels. The system is fully compatible with the Olink Signature Q100 benchtop system and Thermo Fisher’s global network of Olink-equipped laboratories, ensuring reproducibility across sites for multi-centre trials.
For more information, visit: https://shorturl.at/Y59pv
Digital issue: Please click here for more information
